Loading
A phase 1 trial of CBX-250 run by Crossbow Therapeutics, Inc., now recruiting.
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias is a phase 1 interventional study registered as NCT06994676 by Crossbow Therapeutics, Inc., with 72 participants planned, started 2025-07-16. Conditions recorded: High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia and Chronic Myeloid Leukemia. Interventions recorded: CBX-250.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/